HJBC / Shutterstock.com
11 October 2022Big PharmaStaff Writer
French pharma firm inks deal with tech provider
The partnership aims to progress drug discovery and development | Tech platform accelerates trials and provides higher quality trial data.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
18 August 2022 Partnership with San Francisco-based software biotech initially focuses on compounds for five targets | Company uses machine learning to enable structure-based drug design.
Americas
13 September 2022 Deal set to enable faster use of artificial intelligence in drug discovery | Planned AI models to identify novel targets and establish biomarkers of disease.
Editor's picks
Editor's picks
Americas
18 August 2022 Partnership with San Francisco-based software biotech initially focuses on compounds for five targets | Company uses machine learning to enable structure-based drug design.
Americas
13 September 2022 Deal set to enable faster use of artificial intelligence in drug discovery | Planned AI models to identify novel targets and establish biomarkers of disease.
Americas
18 August 2022 Partnership with San Francisco-based software biotech initially focuses on compounds for five targets | Company uses machine learning to enable structure-based drug design.
Americas
13 September 2022 Deal set to enable faster use of artificial intelligence in drug discovery | Planned AI models to identify novel targets and establish biomarkers of disease.